AR123776A1 - Construcciones de ácido nucleico para la activación simultánea de genes - Google Patents

Construcciones de ácido nucleico para la activación simultánea de genes

Info

Publication number
AR123776A1
AR123776A1 ARP210102826A ARP210102826A AR123776A1 AR 123776 A1 AR123776 A1 AR 123776A1 AR P210102826 A ARP210102826 A AR P210102826A AR P210102826 A ARP210102826 A AR P210102826A AR 123776 A1 AR123776 A1 AR 123776A1
Authority
AR
Argentina
Prior art keywords
genes
dna element
recombinase
element according
dna
Prior art date
Application number
ARP210102826A
Other languages
English (en)
Inventor
Simon Austaender
Ulrich Goepfert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR123776A1 publication Critical patent/AR123776A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/507—Recombinase

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se informan novedosas construcciones de ADN y procedimientos de uso de las mismas. La presente invención usa una disposición deliberada de promotores y genes no productivos / inactivos en las hebras codificantes y de molde de las moléculas de ADN, que se convierten en su forma activa mediante la interacción con una recombinasa específica de sitio. Más detalladamente, el elemento de ADN de acuerdo con la presente invención no es funcional con respecto a la expresión del primer y el segundo gen contenidos. Al no ser funcional con respecto a la expresión del primer y el segundo gen, el elemento de ADN de acuerdo con la invención se puede integrar en el genoma de una célula sin el riesgo de que los genes estructurales comprendidos se expresen ya directamente después de la integración. Los genes sólo se expresan una vez que una recombinasa que reconoce y es funcional con las secuencias de reconocimiento de recombinación del elemento de ADN se activa o se introduce en la célula. De este modo, se inicia una inversión de casete mediada por recombinasa (RMCI) entre la primera y la segunda secuencia de reconocimiento de recombinasa mutada en el elemento de ADN genómicamente integrado de la invención. La RMCI da como resultado una inversión de la parte del elemento de ADN de acuerdo con la invención que se localiza entre las dos secuencias de reconocimiento de recombinasa mutantes. De este modo, el primer promotor queda enlazado de forma funcional al primer gen y el segundo promotor queda enlazado de forma funcional al segundo gen. Sólo después de esto, el primer y el segundo gen se transcriben y se expresan las respectivas proteínas codificadas. Por tanto, el elemento de ADN de acuerdo con la presente invención es especialmente útil en la activación simultánea de dos genes dentro de una célula.
ARP210102826A 2020-10-15 2021-10-13 Construcciones de ácido nucleico para la activación simultánea de genes AR123776A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20202009 2020-10-15

Publications (1)

Publication Number Publication Date
AR123776A1 true AR123776A1 (es) 2023-01-11

Family

ID=72964436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102826A AR123776A1 (es) 2020-10-15 2021-10-13 Construcciones de ácido nucleico para la activación simultánea de genes

Country Status (12)

Country Link
US (1) US20220154223A1 (es)
EP (1) EP4229204A1 (es)
JP (1) JP2023546113A (es)
KR (1) KR20230085170A (es)
CN (1) CN116348607A (es)
AR (1) AR123776A1 (es)
AU (1) AU2021363098A1 (es)
CA (1) CA3197726A1 (es)
IL (1) IL302045A (es)
MX (1) MX2023004178A (es)
TW (1) TW202229558A (es)
WO (1) WO2022079082A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202110607WA (en) 2019-04-01 2021-10-28 Tenaya Therapeutics Inc Adeno-associated virus with engineered capsid
WO2024026302A2 (en) * 2022-07-26 2024-02-01 Asimov Inc. Compositions and methods for adeno-associated viral production
CN115691671A (zh) * 2022-10-31 2023-02-03 武汉希望组生物科技有限公司 一种基于三代测序的转录组嵌合体的切分方法、装置
WO2024213494A1 (en) * 2023-04-12 2024-10-17 Cytiva Bioprocess R&D Ab A chromatography system, use thereof, and a method for separating adeno-associated capsids
WO2025054007A1 (en) * 2023-09-06 2025-03-13 Shape Therapeutics Inc. Genetic elements to increase recombinant aav production

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0708658A4 (en) 1993-04-16 1997-05-21 Wistar Inst RECOMBINANT CYTOMEGALOVIRUS VACCINE
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
EP0760682A4 (en) 1995-02-28 1998-09-09 Univ California ANGIOGENIC THERAPY BY GENE TRANSFER
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
CA2230758A1 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
JPH1033175A (ja) 1996-07-24 1998-02-10 Hisamitsu Pharmaceut Co Inc 組換えアデノ随伴ウイルスベクターの製造方法
JP2001500014A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの生産のためにｃｒｅ―ｌｏｘを用いる方法
DE19650714A1 (de) 1996-12-06 1998-06-10 Melchner Harald Von Prof Dr Genfallen-Konstrukt zur Identifizierung und Isolierung von Genen
EP0953647B1 (en) 1996-12-16 2008-05-28 Eisai R&D Management Co., Ltd. Method for preparing retrovirus vector for gene therapy
WO1998027207A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Recombinase-activatable aav packaging cassettes for use in the production of aav vectors
US6303302B1 (en) 1997-11-19 2001-10-16 The Whitehead Institute For Biomedical Research Regulation of fungal gene expression
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP1134287A1 (en) 2000-03-08 2001-09-19 Universite De Geneve A system to control the expression of a given gene using another gene that encodes a polypeptide with recombinant activity
WO2001083797A2 (en) 2000-04-28 2001-11-08 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
US7445929B2 (en) * 2000-05-26 2008-11-04 Dainippon Sumitomo Pharma Co., Ltd. Recombinant adenovirus vector having a reduced side effect
MXPA03000634A (es) 2000-07-21 2004-12-03 Us Agriculture Metodos para el reemplazo, el desplazamiento y acumulacion de adn en genomas eucarioticos.
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US7449179B2 (en) 2000-11-16 2008-11-11 Cornell Research Foundation, Inc. Vectors for conditional gene inactivation
US7074611B2 (en) 2001-04-27 2006-07-11 Gie-Cerbn, Centre Europeen De Recherche En Biologie Et En Medecine (Gie) Method for the stable inversion of DNA sequence by site-specific recombination and DNA vectors and transgenic cells thereof
US20030190746A1 (en) 2002-04-04 2003-10-09 Xiao Xiao Gene expression control system and its use in recombinant virus packaging cell lines
WO2004003180A1 (en) 2002-07-01 2004-01-08 E.I. Du Pont De Nemours And Company Method of controlling gene silencing using site-specific recombination
EP1546397A4 (en) 2002-09-27 2007-10-31 Cold Spring Harbor Lab CELL BASED RNA INTERFERENCE AND ASSOCIATED METHODS AND COMPOSITIONS
PT1625210E (pt) 2003-05-21 2011-03-15 Genzyme Corp Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
US20060110390A1 (en) 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
JP4487068B2 (ja) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
WO2006099615A2 (en) 2005-03-16 2006-09-21 The Johns Hopkins University Adenoviral fiber exchange shuttle system
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
CA2787827C (en) 2010-01-28 2020-11-10 The Children's Hospital Of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
EP2534251A4 (en) 2010-02-09 2013-10-16 Univ Columbia IN VIVO GENREGULATION BY COMBINING A KNOCK-IN-TETO SEQUENCE INTO THE GENOME AND TETRACYCLES-CONTROLLED TRANS-SUPPRESSOR (TTS)
IN2014CN00688A (es) 2011-07-27 2015-04-03 Genethon
US20130058871A1 (en) 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
EP3147295B2 (en) 2011-08-24 2023-11-22 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
IN2014DN08812A (es) 2012-04-18 2015-05-22 Philadelphia Children Hospital
PL3024498T3 (pl) 2013-07-22 2020-05-18 The Children's Hospital Of Philadelphia Wariant aav oraz kompozycje, sposoby i zastosowania transferu genów do komórek, narządów i tkanek
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
WO2015068411A1 (ja) 2013-11-05 2015-05-14 国立大学法人東北大学 遺伝子組み換え非ヒト動物
EP3204050A4 (en) 2014-10-09 2018-04-04 The Regents of The University of California Targeted disruption of a csf1-dap12 pathway member gene for the treatment of neuropathic pain
US20190292561A1 (en) 2015-12-01 2019-09-26 Spark Therapeutics, Inc. Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
CN108699565B (zh) 2015-12-11 2023-08-08 加州理工学院 用于定向腺相关病毒(aav)的靶向肽
WO2017189683A1 (en) 2016-04-26 2017-11-02 Massachusetts Institute Of Technology Extensible recombinase cascades
WO2018096356A1 (en) 2016-11-28 2018-05-31 Horizon Discovery Limited Methods for conditional gene knock-out
KR20240154089A (ko) 2017-02-17 2024-10-24 론자 리미티드 아데노-관련 바이러스 생산을 위한 포유동물 세포
US12404526B2 (en) 2017-06-07 2025-09-02 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
US20200332278A1 (en) 2017-06-16 2020-10-22 Universite De Strasbourg Methods to generate conditional knock-in models
WO2019006390A1 (en) 2017-06-30 2019-01-03 Spark Therapeutics, Inc. AAV VECTOR COLUMN PURIFICATION METHOD
CA3059995A1 (en) 2017-08-28 2019-03-07 The Regents Of The University Of California Adeno-associated virus capsid variants and methods of use thereof
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines

Also Published As

Publication number Publication date
TW202229558A (zh) 2022-08-01
CN116348607A (zh) 2023-06-27
US20220154223A1 (en) 2022-05-19
JP2023546113A (ja) 2023-11-01
MX2023004178A (es) 2023-05-03
EP4229204A1 (en) 2023-08-23
IL302045A (en) 2023-06-01
AU2021363098A1 (en) 2023-05-18
CA3197726A1 (en) 2022-04-21
WO2022079082A1 (en) 2022-04-21
KR20230085170A (ko) 2023-06-13

Similar Documents

Publication Publication Date Title
AR123776A1 (es) Construcciones de ácido nucleico para la activación simultánea de genes
DK1412493T3 (da) Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer
RU2018122636A (ru) Стабильные клеточные линии для продуцирования ретровирусов
JP2018534937A5 (es)
JP2017537615A5 (es)
CY1119905T1 (el) Ρετροϊικα οχηματα τροποποιημενης ζωνης πολυπουρινης
JP2016528894A5 (es)
WO2018192982A3 (en) METHODS OF GENERATING ADENO-ASSOCIATED VIRAL VECTORS
MX2021012851A (es) Cepas y métodos para la producción de proteínas que contienen hemo.
AR112057A1 (es) Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b
RU2019115117A (ru) Synp198, промотор для специфической экспрессии генов в ганглионарных клетках сетчатки, избирательных в отношении направления
RU2019114217A (ru) Геномная инженерия
JP2016539629A5 (es)
JP2016539624A5 (es)
EA202190469A1 (ru) Способы оценки интегрированных нуклеиновых кислот
US20140128292A1 (en) Methods for improving ligation steps to minimize bias during production of libraries for massively parallel sequencing
RU2017121232A (ru) Плазмиды и способ получения вирусных частиц
EP4582541A3 (en) Functional nucleic acid molecule and method
CR20230551A (es) Virus oncolíticos para la expresión modificada del mhc
ES2525707T3 (es) Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
JPWO2021102390A5 (es)
AR122500A1 (es) Ácido nucleico codón-optimizado que codifica la proteína smn1 y su uso
AR043889A1 (es) Secuencias reguladoras de plantas para el control selectivo de la expresion genetica
US20200362345A1 (en) Engineered post-poly a signal rna and uses thereof
Masaki et al. MicroRNA-Responsive ON-OFF Hybrid mRNA Switch for Precise Protein Expression Control